AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
Tempus AI Inc Class A common stock TEM
News
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model
AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation
Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology
Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs
CellCarta Adds Tempus to CDx Commercialization Lab Network
Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications
Tempus Reports Second Quarter 2026 Results
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service
Tempus to Report Second Quarter 2026 Financial Results on July 30
Tempus AI Shares Up After FDA Clearance for In Vitro Diagnostic Device
Tempus Shares Jump on FDA's Special Clearance for Tempus Pixel
United States